Share this article
NEW YORK, May 10, 2021 /PRNewswire/
The Sjogren s syndrome therapeutics market is poised to grow by USD 287.68 million during 2021-2025, progressing at a CAGR of about 4% during the forecast period.
Technavio has announced its latest market research report titled Sjogrens Syndrome Therapeutics Market by Type and Geography - Forecast and Analysis 2021-2025
Our report talks about market scenarios, estimates, the impact of lockdown, and customer behavior.
The report on the Sjogren s syndrome therapeutics market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the presence of a strong drug pipeline.
0
Eli Lilly announced that it has issued royalty-free, non-exclusive voluntary licenses to Indian pharmaceutical manufacturers of generic medicines, Cipla Ltd., Lupin Ltd. and Sun Pharmaceutical Industries Ltd., who are collaborating with Lilly to accelerate and expand the availability of baricitinib in India.
Lilly is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses.
These voluntary licensing agreements will ensure high quality manufacturing and accessibility of baricitinib during this pandemic improving the local treatment options available to positively impact the lives of people who are currently battling Eli Lilly signs agreements with Cipla, Lupin and Sun Pharma -19 in India.
The report on the Sjogren s syndrome therapeutics market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the presence of a strong drug pipeline.
The Sjogren s syndrome therapeutics market analysis includes the type segment and geographic landscape. This study identifies the Initiatives and expected approvals of products as one of the prime reasons driving the Sjogren s syndrome therapeutics market growth during the next few years.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
Sun Pharma signs voluntary licensing agreement with Eli Lilly for expanding access to Baricitinib to help alleviate the burden of Covid-19 in India equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Lilly inks agreement with Cipla, Lupin, Sun Pharma for commercialisation of COVID-19 drug baricitinib
Lilly inks agreement with Cipla, Lupin, Sun Pharma for commercialisation of COVID-19 drug baricitinib
10 May 2021 | News These voluntary licensing agreements will ensure high quality manufacturing and accessibility of baricitinib during this pandemic improving the local treatment options available to positively impact the lives of people who are currently battling COVID-19 in India
Source credit: Shutterstock
Eli Lilly and Company has announced that it has issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla Ltd, Lupin Ltd and Sun Pharmaceutical Industries Ltd, who are collaborating with Lilly to accelerate and expand the availability of baricitinib in India. Lilly is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses.